CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, Kyu-Man | - |
dc.contributor.author | Chang, Hun Soo | - |
dc.contributor.author | Choi, In-Kwang | - |
dc.contributor.author | Ham, Byung-Joo | - |
dc.contributor.author | Lee, Min-Soo | - |
dc.date.accessioned | 2021-09-05T22:02:59Z | - |
dc.date.available | 2021-09-05T22:02:59Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-09 | - |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/102245 | - |
dc.description.abstract | Objective Cytochrome P450 (CYP) enzymatic activity, which is influenced by CYP genetic polymorphism, is known to affect the inter-individual variation in the efficacy and tolerability of antidepressants in major depressive disorder (MDD). Escitalopram is metabolized by CYP2D6, and recent studies have reported a correlation between clinical outcomes and CYP2D6 genetic polymorphism. The purpose of this study was to determine the relationship between the CYP2D6 P34S polymorphism (C188T, rs1065852) and the efficacy of escitalopram treatment in Korean patients with MDD. Methods A total of 94 patients diagnosed with MDD were recruited for the study and their symptoms were evaluated using the 21-item Hamilton Depression Rating scale (HAMD-21). The association between the CYP2D6 P34S polymorphism and the clinical outcomes (remission and response) was investigated after 1, 2, 4, 8, and 12 weeks of escitalopram treatment using multiple logistic regression analysis and chi(2) test. Results The proportion of P allele carriers (PR PS) in remission status was greater than that of S allele homozygotes (SS) after 8 and 12 weeks of escitalopram treatment. Similarly, P allele carriers exhibited a greater treatment response after 8 and 12 weeks of escitalopram treatment than S allele homozygotes. Conclusion Our results suggest that the P allele of the CYP2D6 P34S polymorphism is a favorable factor in escitalopram treatment for MDD, and that the CYP2D6 P34S polymorphism may be a good genetic marker for predicting escitalopram treatrnent outcomes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN NEUROPSYCHIATRIC ASSOC | - |
dc.subject | HUMAN CYTOCHROME-P450 2D6 | - |
dc.subject | PLASMA-CONCENTRATIONS | - |
dc.subject | GENETIC POLYMORPHISMS | - |
dc.subject | PSYCHIATRIC-PATIENTS | - |
dc.subject | ALLELE FREQUENCIES | - |
dc.subject | CLINICAL-RELEVANCE | - |
dc.subject | MOOD DISORDERS | - |
dc.subject | ANTIDEPRESSANT | - |
dc.subject | POPULATION | - |
dc.subject | IMPACT | - |
dc.title | CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Kyu-Man | - |
dc.contributor.affiliatedAuthor | Ham, Byung-Joo | - |
dc.contributor.affiliatedAuthor | Lee, Min-Soo | - |
dc.identifier.doi | 10.4306/pi.2013.10.3.286 | - |
dc.identifier.scopusid | 2-s2.0-84885725443 | - |
dc.identifier.wosid | 000325666600012 | - |
dc.identifier.bibliographicCitation | PSYCHIATRY INVESTIGATION, v.10, no.3, pp.286 - 293 | - |
dc.relation.isPartOf | PSYCHIATRY INVESTIGATION | - |
dc.citation.title | PSYCHIATRY INVESTIGATION | - |
dc.citation.volume | 10 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 286 | - |
dc.citation.endPage | 293 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001812143 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | HUMAN CYTOCHROME-P450 2D6 | - |
dc.subject.keywordPlus | PLASMA-CONCENTRATIONS | - |
dc.subject.keywordPlus | GENETIC POLYMORPHISMS | - |
dc.subject.keywordPlus | PSYCHIATRIC-PATIENTS | - |
dc.subject.keywordPlus | ALLELE FREQUENCIES | - |
dc.subject.keywordPlus | CLINICAL-RELEVANCE | - |
dc.subject.keywordPlus | MOOD DISORDERS | - |
dc.subject.keywordPlus | ANTIDEPRESSANT | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | CYP2D6 polymorphism | - |
dc.subject.keywordAuthor | Major depressive disorder | - |
dc.subject.keywordAuthor | Escitalopram | - |
dc.subject.keywordAuthor | Treatment response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.